Journal of Phytonanotechnology and Pharmaceutical Sciences 5(2): 7-15, 2025

Online ISSN:2583-0376

http://jpps.ukaazpublications.com

DOI: http://dx.doi.org/10.54085/jpps.2025.5.2.2

Journal of Phytonanotechnology and Pharmaceutical Sciences



Review Article : Open Access

# The microbiome's role in health and diseases: Emerging therapeutic interventions and challenges

**Anas Islam, Badruddeen◆, Mohammad Irfan Khan, Juber Akhtar, Asad Ahmad, Mohammad Ahmad*, Akash Srivastava and Shaiber Siddiqui**

*Faculty of Pharmacy, Integral University, Lucknow-226026, Uttar Pradesh, India*

**Article Info**

**Article history**

Received 17 April 2025

Revised 23 May 2025

Accepted 24 May 2025

Published Online 30 June 2025

**Keywords**

Human microbiome

Dysbiosis

Fecal microbiota transplantation

Engineered bacteria

Microbiome-derived drugs

Therapeutic interventions

**Abstract**

The human microbiome, the diverse collection of microorganisms that inhabit our body, is essential for our health and well-being. However, when the microbiome is disturbed or imbalanced, known as dysbiosis, it can trigger or worsen various diseases, such as gastrointestinal, metabolic, cardiovascular, and neurological disorders. The latest research underscores the significant influence of the microbiome, particularly the gut microbiome, on health and disease, affecting various aspects of physiology and immunity. Emerging therapies targeting the microbiome, including fecal microbiota transplantation (FMT), engineered bacteria, and microbiome-derived drugs, are also spotlighted, reflecting their potential in advancing medical treatments. FMT, which involves transferring fecal matter from a healthy donor to a patient, has proven effective in treating recurrent *Clostridium difficile* infections and is being tested for other indications. Engineered bacteria are designed to deliver specific drugs or modulate the immune system in the gut. Microbiome derived drugs are molecules produced by the microbiome that have therapeutic potential. However, translating microbiome research into clinical practice faces many challenges, such as the variability of the microbiome among individuals, the difficulty of producing and standardizing live bacterial products, and the regulatory issues involved. To overcome these challenges, we need a multidisciplinary approach that combines microbiology, immunology, genomics, and clinical science. This article emphasizes the importance of the microbiome in human health and disease and showcases the promise of microbiome-based therapies, while acknowledging the obstacles that need to be addressed to achieve their clinical application.

## 1. Introduction

The microbiome of a human is a complex and ever-changing collection of microbes that inhabit and colonise the human body, exerting a pivotal influence on both well-being and illness. The environment consists of a combination of bacteria, viruses, fungi, and their genetic material, and is widely recognized as a vital component that engages with the host organism through several mechanisms. The microbiome and metagenome are integral to human health, influencing disease states and representing a new frontier in genetics (Cho and Blaser, 2012). The microbiome has been connected to disorders including obesity, inflammatory bowel disease, and autism through technological advancements in sequencing and analysis. This has opened up possibilities for therapy based on the microbiota (Gilbert *et al.,* 2018; Althani *et al.,* 2016). The microbiome is described as a newly recognized human organ with its physiology and pathology, and its alteration can lead to health issues (Baquero and Nambela, 2012). Microbiome research is revolutionising our understanding of host-microbe interactions, metabolism, immunity, and even oncogenesis (Blaser, 2014). The diversity of the microbiota presents challenges in correlating microbiota composition with health and disease, but it holds potential for future clinical diagnostics and treatments (Eloe-Fadrosh, 2013). The microbiome's role in child health is significant, influencing the development of the immune system and protecting against pathogens (Putignani *et al.,* 2014). Perturbations in the microbiome can lead to diseases, and understanding this relationship is crucial for developing therapeutic interventions (Aggarwal *et al.,* 2022).

The microbiome, sometimes known as the "forgotten organ," is a complex network of microorganisms, such as bacteria, fungi, parasites, and viruses, that exist within the human body. The community in question assumes a crucial role in the overall health and well-being of individuals, exerting influence over a diverse array of physiological processes and illness conditions (Sirisinha, 2016; El-Sayed *et al.,* 2021). The microbiome is formed at birth and is impacted by a number of things, including nutrition, exercise, travel, disease, menstrual cycles, and treatments. The microbiome is comparatively constant in healthy people, indicating that it plays a role in preserving health (D'Argenio and Salvatore, 2015). It is essential for the immune system's growth and education, as well as the prevention of infections and non-communicable illnesses, including obesity, metabolic syndromes, and inflammatory disorders (Sirisinha, 2016). Particularly, it has been demonstrated that the gut microbiota regulates the gut-brain axis, impacting pain, emotion, anxiety, and cognitive function. The two-way exchange of information implies that neurological problems might also be influenced by the microbiota (Mohajeri *et al.,* 2018; Flowers and

**Corresponding author: Dr. Badruddeen**

*Professor, Faculty of Pharmacy, Integral University, Lucknow-226026, Uttar Pradesh, India*

**E-mail: badarmiracle@gmail.com**

**Tel.: +91-9918196188**

Ellingrod, 2015). Additionally, the immune system and gut-brain transmission are known to be impacted by microbial metabolites, including short-chain fatty acids (Mohajeri *et al.,* 2018). Numerous diseases, including autoimmune disorders, obesity, inflammatory bowel disease, allergy diseases, and even neuropsychiatric conditions, have been related to dysbiosis, or an imbalance in the microbiome (Khanna and Tosh, 2014). The efficiency and side effects of pharmacologic treatments used to treat these illnesses are also influenced by the microbiota (Flowers and Ellingrod, 2015). Our knowledge of the microbiome's function in health and illness, particularly its potential role in cancer therapy, has improved recently due to advancements in sequencing and bioinformatics (Cong *et al.,* 2018). The microbiome's impact on gastrointestinal health is particularly significant, as it helps maintain mucosal barrier integrity and modulates host immunity to prevent excessive inflammation and disease (Sanders *et al.,* 2021).

A disturbance in the microbial communities that reside on and inside the human body is the hallmark of dysbiosis, often referred to as dysbacteriosis, which is an imbalance in the microbiome. This imbalance can lead to changes in the functional composition, metabolic activities, or local distribution of these microorganisms (Petersen and Round, 2014). Dysbiosis commonly affects areas like the gut, skin, and vaginal flora, where normally dominant species may decrease, allowing other species to overgrow and potentially cause harm. Small intestine bacterial overgrowth (SIBO) and small intestinal fungal overgrowth (SIFO) are disorders caused by dysbiosis in the gut, which can be attributed to a variety of factors, including dietary modifications, antibiotic usage, stress, infections, and some medical therapies. From minor symptoms like cramps, diarrhea, and constipation to more serious chronic conditions like chronic fatigue, gastrointestinal distress, inflammation, skin issues, mental health disorders, and even chronic diseases like inflammatory bowel disease (IBD), obesity, diabetes, and autoimmune conditions, dysbiosis has a significant impact on health. Additionally, dysbiosis has been connected to diseases including cancer, cardiovascular disease, and irritable bowel syndrome (IBS). Comprehending dysbiosis is essential as it can affect all facets of health, underscoring the need to preserve a well-balanced and varied microbiome for general health and illness prevention (Wilkins *et al.,* 2019).

The objective of this article is to comprehensively explore the crucial role of the human microbiome in health and disease, emphasizing the transformative potential of emerging microbiome-based therapeutic interventions. It seeks to highlight the significant impact of dysbiosis on various diseases and to showcase the latest advancements in treatments such as fecal microbiota transplantation, engineered bacteria, and microbiome-derived drugs. Additionally, the article aims to address the multifaceted challenges encountered in translating microbiome research into clinical applications, advocating for a multidisciplinary approach to overcome these obstacles and fully harness the therapeutic promise of the microbiome.

## 2. The microbiome and human health

### 2.1 The symbiotic relationship between humans and their microbiome

One complicated and crucial component of human health and illness is the symbiotic link that exists between humans and their microbiota. Over time, this link has changed, impacting a number of physiological processes, such as immune system development, metabolic processes, and the possibility of treatments. According to Lee and Mazmanian (2010), the human microbiota is essential in determining how the adaptive immune system develops and functions. Particular microbial species have an influence on inflammation and autoimmunity as well as T cell population differentiation. Changes in the relationship between humans and microbes have been linked to immune-mediated illnesses like spondyloarthropathies, type 1 diabetes, and inflammatory bowel disease. As a result, the gut microbiome has become a target for cutting-edge treatments like probiotics and fecal microbiota transplants (Costello *et al.,* 2015). Microbiota serves as a potent immunomodulator, affecting host physiology, metabolism, and immune system regulation; disruptions in this symbiosis can lead to various pathologies, and manipulation of the microbiome is being explored for health improvement and disease management (Sharma *et al.,* 2022). Lifestyle changes may disrupt the essential symbiosis between humans and their microbiome, often correlating with chronic disorders, and the study of this symbiosis is crucial for developing diagnostic tools, preventive nutrition, and therapies for the 'microbial human' (Doré and Ortega, 2023). The gut microbiota, considered an internal "microbial organ," has a significant role in modulating human metabolic phenotypes, particularly through the gut-liver axis, although the molecular basis of these interactions and the role of individual bacterial species are not fully understood (Li, 2011). A core intestinal microbiome is shared among humans, but individual differences exist due to genes, species, enterotypes, and microbial diversity; metagenomic analysis has stratified health and disease states based on microbiome gene count, with dysbiosis linked to chronic diseases and conditions (Malard *et al.,* 2021).

### 2.2 The impact of the microbiome on physiology and immunity

The influence of the microbiome on immunity and physiology is a complex subject that has attracted a lot of attention lately. The microbiome, especially the gut microbiome, is essential for many physiological functions, such as immune system development, metabolism, and immunological homeostasis maintenance. It affects the defensive systems of the body, influencing both healthy and unhealthy states. The gut microbiota influences cancer immunology, which may impact the course of illnesses like multiple myeloma and the efficiency of cancer therapies, including immunotherapy, chemotherapy, and hematopoietic stem cell transplantation. Treatment-related toxicity may be decreased by microbiota-modulating techniques such as nutrition, probiotics, and prebiotics (Brevi *et al.,* 2022). The intestinal epithelium functions as a barrier that modifies different hematopoietic cells' chemotaxis. The host mucosal immune system develops in part because of the microbiota and its metabolites. Obesity, liver illness, and problems with lung immunity can all be caused by disruptions in the microbiota-immune axis (Kanellopoulos, 2014).

The gut microbiome has a major impact on how well cancer immunotherapy works. Preclinical and early clinical research shows promise in manipulating the makeup of microbiota to maximize immunotherapy results (Fessler *et al.,* 2019). Atopic dermatitis has been connected to dysbiosis, or alterations in the microbiome. The potential for microbiome-targeted therapeutics is shown by the possibility of manipulating the gut and skin microbiota to treat

this ailment (Lee *et al.,* 2018). Intestinal microbiota has a role in stressor-induced immunomodulation, which modifies systemic immunological activity and infection susceptibility. Stressors alter the gut microbiota's makeup, which affects immunological responses (Bailey, 2012). Longman and Littman (2015) have shown a functional relationship between the gut microbiome and the activation of mucosal and systemic immune cells that underlie autoimmunity. This highlights the significance of microbial-host interactions in regulating immune activities and possibly discovering therapeutic targets (Longman and Littman, 2015).

#### 2.2.1 Gut microbiome's influence on gastrointestinal health

Chronic illnesses, ranging from metabolic disease to gastrointestinal problems and colorectal cancer, are influenced by the gut microbiota. The gut microbiota is shaped by both environmental and nutritional variables. It produces short-chain fatty acids that aid in lipid homeostasis and reduce inflammation, as well as mediating positive effects through the fermentation of dietary fiber. Predicting a person's reaction to probiotic therapies requires an understanding of their initial microbial composition (Hills *et al.,* 2019). The synthesis of nutrients, including short-chain fatty acids, B vitamins, and vitamin K, is only one of the many functions that the gut microbiota performs in human nutrition and metabolism. By interacting with receptors on epithelial cells, it also affects the metabolism of the host, perhaps contributing to metabolic syndrome, diabetes, and non-alcoholic fatty liver disease. According to study, the microbiota may have a role in the pathophysiology of various illnesses (Ramakrishna, 2013).

The human gut microbiota is established throughout infancy by a variety of factors, including nutrition. In maintaining immunological and metabolic equilibrium as well as defense against infections, the microbiome is essential. Inflammatory illnesses and infections have been linked to dysbiosis, or a change in the makeup of gut microorganisms (Thursby and Juge, 2017). The gut's beneficial bacterial species can become more diverse and richer through exercise, which benefits the host and improves health. Exercise influences microbial composition through environmental factors that have an impact on health and illness prevention (Monda *et al.,* 2017). Dietary proteins can modify the makeup and activity of the gut microbiota, hence exerting an influence on overall health. The microbiota is influenced by the amino acid content and digestibility of proteins, resulting in notable alterations in microbial metabolites that can have both beneficial and detrimental effects on health. It is advisable to maintain a harmonious proportion of protein and carbs in order to sustain a healthy gut microbiota and mitigate the likelihood of developing disorders (Ma *et al.,* 2017).

#### 2.2.2 Connections to metabolic, cardiovascular, and neurological health

The gut microbiota exerts a significant influence on the metabolic processes of the host, hence playing a role in the pathogenesis of obesity, type 2 diabetes, and several other metabolic disorders. It has an impact on the energy production generated from food and regulates the presence of dietary or host-derived substances that modify metabolic pathways. The comprehension of these connections has the potential to yield innovative therapeutic approaches for metabolic disorders (Tremaroli and Bäckhed, 2012). The involvement of gut bacteria in cardiovascular health and illness is of considerable importance. Atherosclerosis, hypertension, heart failure, and chronic renal disease have been associated with dysbiosis. The metabolic capacity of the gut microbiota, which encompasses the synthesis of compounds such as trimethylamine N-oxide (TMAO), exerts an impact on the progression of cardiovascular disease. According to a study, the modulation of gut microbiota composition offers a promising approach for therapeutic intervention in cardiovascular disorders. The concept of the gut-brain axis underscores the reciprocal interaction between the gut bacteria and the central nervous system, exerting influence on several aspects such as mood, behavior, and neurological illnesses (Tang and Hazen, 2017). Neurodevelopmental, psychiatric, and neurodegenerative illnesses have been linked to disturbances in microbial ecosystems. Current research is in the process of elucidating the underlying processes by which the gut microbiota influences the brain, hence providing valuable insights into innovative therapy strategies for neurological disorders (Gwak and Chang, 2021).

### 2.3 Examples of diseases associated with dysbiosis

Dysbiosis can impact how energy is derived from food, how fat is stored, and how metabolic pathways are altered, all of which can lead to the development of obesity and metabolic syndrome (Turnbaugh *et al.,* 2006). Changes in the makeup of the gut microbiota might affect how glucose is metabolized, which can result in insulin resistance and type 2 diabetes (Qin *et al.,* 2012). Trimethylamine N-oxide (TMAO), which has been connected to atherosclerosis and an elevated risk of heart disease, is one of the metabolites that the gut microbiota may create from dietary components (Wang *et al.,* 2011). According to the gut-brain axis, dysbiosis is associated with mental health issues, including anxiety and depression and may have an impact on brain function and behavior (Cryan and Dinan, 2012). Early-life changes in gut microbiota have been linked to a higher chance of allergic illness development, including atopic dermatitis and asthma (Abrahamsson *et al.,* 2012).

## 3. Emerging therapeutic interventions

### 3.1 Fecal microbiota transplantation (FMT)

In contemporary medicine, fecal microbiota transplantation (FMT) has become an essential treatment strategy, especially for recurrent *C. difficile* infection (CDI). It is now being investigated for a broader range of gastrointestinal and non-gastrointestinal disorders. To restore the natural flora of the patient's gut, fecal microbiota from a healthy donor is transferred to the patient's digestive tract using FMT. In addition to being very successful in treating recurrent CDI, this method may also be used to treat obesity, irritable bowel syndrome, and inflammatory bowel disease (IBD). There are several ways to carry out the process, such as *via* oral capsules, nasogastric tube, or colonoscopy (Brandt and Aroniadis, 2013). For recurrent CDI, FMT has shown a primary cure rate of 91% and a secondary cure rate of 98%. Due to its effectiveness and decreased recurrence risk, a sizable percentage of patients prefer FMT over conventional antibiotic therapies. According to a study, the transplanted fecal matter may be able to help patients restore a healthy gut microbiota due to its high success rate (Zhang *et al.,* 2012). While FMT has shown great promise, standardisation of the procedure is necessary to enhance its success and minimise risks. This includes donor

screening, fecal sample preparation, and the method of transplantation. Future research is needed to expand the indications for FMT beyond CDI to other diseases linked to gut microbiota dysbiosis (Bhutiani *et al.,* 2018). Despite its effectiveness, concerns about the safety of FMT, particularly in immunocompromised patients, necessitate careful donor screening and adherence to protocols to prevent transmission of infections. Regulatory approval and guidance are essential to ensure patient safety and efficacy of FMT treatments (Tan and Johnson, 2019).

### 3.2 Engineered bacteria

Engineered bacteria are emerging as a revolutionary class of therapeutic interventions, harnessing the power of synthetic biology to treat a wide range of diseases. These genetically modified microorganisms are designed to perform specific tasks within the human body, such as producing therapeutic agents, regulating immune responses, or directly targeting pathogens or diseased cells. Advances in synthetic biology have equipped researchers with a diverse set of genetic tools to engineer microbes capable of sensing environmental cues, executing programmed responses, and delivering therapeutic agents. This includes the development of sensors, regulators, memory circuits, and biocontainment systems, enabling the creation of living therapeutics that can operate autonomously within the body (Pedrolli *et al.,* 2019). The human microbiome plays a crucial role in health and disease, influencing metabolism, immunity, and even behavior. Engineering bacteria to modulate the microbiome opens up possibilities for treating conditions associated with dysbiosis, such as metabolic syndrome, inflammatory bowel diseases, and infections. Challenges include ensuring stable colonization, developing clinically relevant biosensors, and addressing safety concerns (Mimee *et al.,* 2016).

Engineered bacteria have been tailored for a variety of therapeutic applications, including autoimmune diseases, cancer, metabolic diseases, and infectious diseases. These applications leverage bacteria's ability to home to specific tissues, produce therapeutic molecules, and modulate the immune system. Significant work has been done to engineer bacteria that can target tumors, treat metabolic disorders, and deliver gene therapy vectors (Paton *et al.,* 2012). While engineered bacteria hold great promise as therapeutic agents, there are several challenges to overcome before widespread clinical application. These include optimizing delivery methods, ensuring long-term functionality and safety within the human body, and navigating regulatory pathways. Ongoing research focuses on creating more robust and versatile microbial platforms that can be tailored to a wider range of diseases, improving our ability to treat chronic conditions and reduce reliance on traditional drugs (Álvarez and Fernández, 2017).

### 3.3 Microbiome-derived drugs

Microbiome-derived drugs represent a pioneering approach in leveraging the complex interactions between the human microbiome and health outcomes for therapeutic purposes. The vast microbial ecosystem residing in and on the human body, particularly in the gut, is a rich source of novel bioactive compounds that can be harnessed to develop new therapies for a range of diseases. The human microbiome, particularly the gut microbiome, is increasingly recognized as a critical factor in health and disease, offering a new frontier for drug development. The exploration of the microbiome's composition and functionality has led to the identification of microorganism-based therapeutics targeting autoimmune, metabolic, and infectious diseases. This involves live bacterial therapies, engineered microbes, and microbial derived metabolites, challenging traditional drug development paradigms and requiring novel approaches to pharmacokinetics, pharmacodynamics, and safety assessments (Lamousé-Smith *et al*., 2020). Microorganisms have long been a source of therapeutic agents, with many drugs derived from natural products of bacteria and fungi. These include a wide range of antibiotics, as well as compounds with applications beyond antibacterial therapy, such as statins and immunosuppressants. The screening of microorganisms continues to yield valuable leads for new drugs, highlighting the untapped potential of microbial metabolites in various medical fields (Amedei and D'Elios, 2012).

The microbiome modulates the efficacy and toxicity of drugs through its metabolic activities. Understanding how microbial enzymes metabolize drugs can inform the development of microbiome-based strategies to improve therapeutic outcomes. This includes manipulating the microbiome through diet, probiotics, and engineered bacteria to enhance drug efficacy and reduce adverse effects, representing a step toward personalized medicine (Kelly, 2019). The diverse biochemical capabilities of the human gut microbiome suggest that it can significantly influence individual responses to drugs by affecting their metabolism. Developing methods to map these interactions can lead to personalized approaches to drug administration, optimizing therapeutic efficacy based on an individual's microbiome composition (Javdan *et al.,* 2020). The microbiome's interaction with drugs is bidirectional; not only can the microbiome affect drug metabolism, but drugs, especially antibiotics, can significantly alter the microbiome's composition. Understanding these interactions is crucial for managing drug efficacy, side effects, and the development of antibiotic resistance, and for the exploration of microbiota as a target for enhancing drug effects (Weersma and Fu, 2020). Table 1 outlines the main emerging therapeutic interventions targeting the microbiome as described in the manuscript, providing insights into their potential applications, the successes achieved so far, and the significant challenges that need to be addressed to fully realize their clinical utility.

## 4. Challenges in microbiome research and therapeutic development

### 4.1 Individual variability of the microbiome

The individual variability of the microbiome poses significant challenges for microbiome research and the development of therapeutic interventions. While inter-individual variability has been seen as a weakness in microbiota-gut-brain research, it presents a strength. In clinical microbiome research, acknowledging and comprehending this heterogeneity can aid in methodically comprehending the variety in microbiota composition, interpreting null data, and perhaps enhancing the efficacy of therapeutic interventions (Wissel and Smith, 2019). The great genetic and metabolic variety of the gut microbiome is important for illness causation, prognosis, and treatment-related side effects. It is

promising as a source of new therapeutics as well as for stratifying current treatments. However, in order to successfully incorporate the microbiome into clinical care, a number of obstacles must be removed, including standardizing testing and reporting procedures, confirming results in larger cohorts, and comprehending how the microbiome contributes to illness and therapy (Schupack *et al.,* 2021). With an emphasis on both additive and subtractive methods of microbiota manipulation, the development of therapies aimed at the microbiome has exploded. Developing treatments tailored to certain body geographies, obtaining stable colonization, finding therapeutically useful biosensors, guaranteeing the durability of designed synthetic gene circuits, and resolving safety and biocontainment issues are among the difficulties (Mimeeand Lu, 2016).

**Table 1: Overview of emerging microbiome-based therapeutic interventions: Applications, successes, and challenges**

| Therapeutic intervention | Description | Applications and success | Challenges and considerations |
|---|---|---|---|
| **Fecal microbiota transplantation (FMT)** | Transferring fecal bacteria from a healthy donor to a patient to restore the gut's normal flora | Highly effective against recurrent *C. difficile* infection (CDI), potential for treating IBD, IBS, and obesity | Standardization of procedure, donor screening and fecal sample preparation, regulatory approval and safety concerns |
| **Engineered bacteria** | Genetically modified microorganisms are designed to perform specific tasks, such as producing therapeutic agents or regulating immune responses | Autoimmune diseases<br>Cancer<br>Metabolic diseases<br>Infectious diseases | Ensuring stable colonization and functionality, safety within the human body, regulatory pathways and ethical considerations |
| **Microbiome-derived drugs** | Utilising the complex interactions between the human microbiome and health to develop new therapies | Autoimmune, metabolic, and infectious diseases, live bacterial therapies, engineered microbes, microbial-derived metabolites | Identifying bioactive compounds, understanding pharmacokinetics and pharmacodynamics. Addressing the variability of the microbiome among individuals |

### 4.2 Production and standardization of bacterial products

The production and standardization of bacterial products pose several challenges in the field of microbiome research and therapeutic development. The development of therapeutics targeting the microbiota often involves engineered bacteria designed to produce therapeutic payloads. Developing treatments tailored to target body areas, attaining stable colonization, finding therapeutically useful biosensors, guaranteeing the durability of modified gene circuits, and resolving safety and biocontainment issues are some of the difficulties this method encounters (Mimee and Lu, 2016). The potential therapeutic uses of microbial synthesis of natural products and biologics have sparked significant interest in this field. A notable accomplishment in this domain is the creation of resilient microorganisms serving as cell manufacturers. However, challenges remain in improving yields, overcoming the limitations of microbial systems, and generating novel molecules through comprehensive engineering approaches (Pham *et al.,* 2019). While microbial systems offer advantages for the production of recombinant proteins, including high yields and ease of manipulation, challenges such as proper folding, post-translational modifications, and product purity must be addressed. Advances in genetic engineering and process optimization are crucial for overcoming these obstacles and ensuring the successful production of recombinant pharmaceuticals in microbial hosts (Graumann and Premstaller, 2006).

### 4.3 Regulatory and ethical issues

#### 4.3.1 Navigating the approval process for new microbiome-based therapies

The development and regulatory approval of microbiome-based therapies, including FMT, face unique challenges due to the complex and variable nature of microbial communities. Under "enforcement discretion," the U.S. Food and Drug Administration (FDA) allow the use of FMT for *C. difficile* infection (CDI) that does not respond to standard therapies. This underscores the need for a balanced regulatory framework that protects patient access to novel treatments while giving priority to efficacy, safety profile, and long-term effects research. In order to progress microbiome therapies, guidelines for preparing investigational new drug applications for FMT studies highlight the regulatory experience needed to handle this process and the significance of cooperation between scientists, physicians, and regulatory agencies (Grigoryan *et al.,* 2020; Kelly *et al*., 2014).

#### 4.3.2 Ethical considerations in FMT and engineered bacteria

Ethical issues surrounding FMT and the use of engineered bacteria for therapeutic purposes are multifaceted. These include obtaining informed permission, figuring out who qualifies as a "suitable healthy donor," evaluating safety and risk, commercialization and the possible exploitation of vulnerable patients, and the ramifications for public health. Ensuring informed consent, especially in the context of vulnerable patients and balancing access to promising treatments with the need for comprehensive research on long-term effects, is paramount. The selection of donors and standardization of protocols for screening donor stool are critical for minimising risks and ensuring the safety of FMT treatments. Additionally, the commercialization of microbiome-based therapies raises ethical questions regarding the exploitation of patients and donors, necessitating careful regulatory oversight to prevent abuses (Ma *et al.,* 2017).

## 5. Multidisciplinary approaches to overcoming challenges

### 5.1 Integrating microbiology, immunology, genomics, and clinical science

Multidisciplinary approaches that integrate microbiology, immunology, genomics, and clinical science are essential for overcoming challenges in microbiome research and therapeutic development. These approaches leverage the strengths of each discipline to create a comprehensive understanding of complex biological systems and diseases, leading to innovative solutions for

healthcare. The integration of large and diverse datasets from genomic medicine presents informatics challenges such as knowledge representation and data integration. Utilizing technologies in data integration may provide solutions to these challenges, helping to revolutionise healthcare by applying the molecular basis of disease to patient care (Louie *et al.,* 2007). Knowledge integration involves methods for generating, synthesizing, and engaging stakeholders around rapidly emerging information on health-related genomic technologies. This process is pivotal in translating genomic research into clinical practice, encompassing knowledge management, synthesis, and translation (Khoury *et al.,* 2012).

Efforts to integrate the teaching of basic sciences, clinical sciences, and biopsychosocial issues in medical education highlight the importance of interdisciplinary curricula. This approach promotes a more holistic understanding of patient care and the underlying biological mechanisms of disease (Schmidt, 1998). Experiences in integrating genomics into nursing practice demonstrate the feasibility and benefits of incorporating genomic data into the clinical setting. This integration supports personalized medicine by enabling healthcare professionals to tailor treatments based on individual genetic profiles (Flynn *et al.,* 2019). The combination of bioinformatics and molecular biology allows researchers to conduct advanced studies based on high-throughput data. Integrated education in these fields prepares scientists to tackle complex research challenges by understanding both the computational and biological aspects of genomics and transcriptomics (Pucker *et al.,* 2018).

### 5.2 Future directions and innovations in microbiome research

The development of more sophisticated computational models and bioinformatics tools will be crucial for analyzing the vast amounts of data generated by microbiome studies. These tools will enable researchers to better understand the complex interactions within microbial communities and between these communities and their hosts or environments (Chowdhury and Fong, 2020). Future research will increasingly integrate multi-omics data, including genomics, transcriptomics, proteomics, metabolomics, and more. This integration will provide a more comprehensive understanding of microbial functions and interactions, offering insights into the mechanisms through which microbiomes influence health and disease (Graw *et al.,* 2021). Innovations in microbiome engineering and synthetic biology will enable the design of microbial communities with desired properties. This could lead to the development of targeted therapies for diseases, enhanced probiotics, and engineered bacteria that can degrade environmental pollutants or produce valuable biochemicals (Kang *et al.,* 2020; Dou *et al.,* 2018). There will be a shift towards longitudinal microbiome studies that track changes in microbial communities over time, offering insights into how the microbiome evolves with age, health status, and in response to environmental exposures. Personalized microbiome profiling will also become more common, paving the way for personalized medicine approaches that consider an individual's unique microbial composition (Zhou *et al.,* 2024; Logotheti *et al.,* 2021).

Beyond human health, future research will explore the microbiomes of animals, plants, and ecosystems to understand their roles in biodiversity, agriculture, and environmental sustainability. This research will have implications for conservation efforts, food production, and understanding global biogeochemical cycles (Yadav *et al.,* 2017; Suman *et al.,* 2022).Deepening our understanding of the interactions between the microbiome and the immune system will be a key area of future research. This includes elucidating how microbial communities influence immune development, function, and the pathogenesis of immune-mediated diseases. Such insights could lead to novel immunotherapies and vaccines (Kogut *et al.,* 2020; Clavel *et al.,* 2017). As microbiome research advances, addressing the ethical, legal, and social implications will be essential. This includes considerations around privacy and data sharing, the use of genetically modified organisms, and the equitable distribution of benefits derived from microbiome research (Chuong *et al.,* 2017; Rhodes *et al.,* 2013). Collaborative international research initiatives will play a vital role in advancing microbiome science. Sharing data and resources across borders will enable a more comprehensive understanding of the human microbiome and its variations across different populations and environments (Hadrich, 2018; Cullen *et al.,* 2020).

## 6. Conclusion

In conclusion, the microbiome's complicated role in human health and disease has been increasingly recognized as a cornerstone of biomedical research. The vast communities of microorganisms residing within and on the human body are not mere passengers but active participants in maintaining health, influencing the development of diseases, and shaping the efficacy of therapies. From modulating immune responses to affecting drug metabolism, the microbiome presents a complex interplay with the host that is critical to understanding pathogenesis and therapeutic interventions. The exploration into microbiome-based therapies heralds a promising frontier in medicine, offering the potential to revolutionize treatment paradigms across a spectrum of diseases. Whether it is through fecal microbiota transplantation (FMT) for treating *C. difficile* infections or engineered microbial consortia for targeted disease intervention, these therapies exemplify the innovative approaches leveraging the microbiome for health benefits. Moreover, the potential for personalized medicine, where treatments are tailored based on an individual's microbiome composition, highlights the transformative power of microbiome research. However, to fully understand the therapeutic potential of the microbiome, several challenges must be addressed. These include the need for advanced computational tools for analyzing complex microbiome datasets, the integration of multi-omics data to elucidate the mechanisms by which the microbiome influences health and disease, and the development of ethical, legal, and social frameworks to navigate the novel implications of microbiome-based interventions. Furthermore, interdisciplinary collaborations and global partnerships will be pivotal in overcoming these challenges, necessitating a concerted effort from researchers, clinicians, policymakers, and patients alike. By fully acknowledging the complexities of the microbiome, promoting advancements in research and therapeutic innovation, and carefully navigating the ethical and regulatory landscapes, we are on the brink of uncovering revolutionary, effective, and potentially customized treatments that have the potential to revolutionize healthcare practices and therapeutic approaches for a wide range of health conditions.

## Conflict of interest

The authors declare no conflicts of interest relevant to this article.

## References


**Abrahamsson, T. R.; Jakobsson, H. E.; Andersson, A. F.; Björkstén, B.; Engstrand, L. and Jenmalm, M. C. (2012).** Low diversity of the gut microbiota in infants with atopic eczema. J. Allergy Clin. Immunol., **129**(2):434-440.

**Aggarwal, N.; Kitano, S.; Puah, G. R.; Kittelmann, S.; Hwang, I. Y. and Chang, M. W. (2022).** Microbiome and human health: Current understanding, engineering, and enabling technologies. Chem. Rev., **123**(1):31-72.

**Althani, A. A.; Marei, H. E.; Hamdi, W. S.; Nasrallah, G. K.; El Zowalaty, M. E.; Al Khodor, S.; Al Asmakh, M.; Abdel Aziz, H. and Cenciarelli, C. (2016).** Human microbiome and its association with health and diseases. J. Cell. Physiol., **231**(8):1688-1694.

**Amedei, A. and D'Elios, M. M. (2012).** New therapeutic approaches by using microorganism-derived compounds. Curr. Med. Chem., **19**(22), 3822-3840.

**Bailey, M. T. (2012).** The contributing role of the intestinal microbiota in stressor-induced increases in susceptibility to enteric infection and systemic immunomodulation. Horm. Behav., **62**(3):286-294.

**Baquero, F. and Nombela, C. (2012).** The microbiome as a human organ. Clin. Microbiol. Infect., **18**:2-4.

**Bhutiani, N.; Schucht, J. E.; Miller, K. R. and McClave, S. A. (2018).** Technical aspects of fecal microbial transplantation (FMT). Curr. Gastroenterol. Rep., **20**:1-6.

**Blaser, M. J. (2014).** The microbiome revolution. J. Clin. Invest., **124**(10):4162-4165.

**Brandt, L. J. and Aroniadis, O. C. (2013).** An overview of fecal microbiota transplantation: Techniques, indications, and outcomes. Gastrointest. Endosc., **78**(2):240-249.

**Brevi, A.; Cogrossi, L. L. and Bellone, M. (2022).** The insider: Impact of the gut microbiota on cancer immunity and response to therapies in multiple myeloma. Front. Immunol., **13**:845422.

**Cho, I. and Blaser, M. J. (2012).** The human microbiome: At the interface of health and disease. Nat. Rev. Genet., **13**(4):260-270.

**Chowdhury, S. and Fong, S. S. (2020).** Computational modeling of the human microbiome. Microorganisms, **8**(2):197.

**Chuong, K. H.; Hwang, D. M.; Tullis, D. E.; Waters, V. J.; Yau, Y. C.; Guttman, D. S. and O'Doherty, K. C. (2017).** Navigating social and ethical challenges of biobanking for human microbiome research. BMC Med. Ethics, **18**:1-10.

**Clavel, T.; Gomes Neto, J. C.; Lagkouvardos, I. and Ramer Tait, A. E. (2017).** Deciphering interactions between the gut microbiota and the immune system *via* microbial cultivation and minimal microbiomes. Immunol. Rev., **279**(1):8-22.

**Cong, J. and Zhang, X. (2018).** How human microbiome talks to health and disease. Eur. J. Clin. Microbiol. Infect. Dis., **37**(9):1595-1601.

**Costello, M. E.; Robinson, P. C.; Benham, H. and Brown, M. A. (2015).** The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. Best Pract. Res. Clin. Rheumatol., **29**(2):202-212.

**Cryan, J. F. and Dinan, T. G. (2012).** Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci., **13**(10):701-712.

**Cullen, C. M.; Aneja, K. K.; Beyhan, S.; Cho, C. E.; Woloszynek, S.; Convertino, M.; McCoy, S. J.; Zhang, Y.; Anderson, M. Z.; Alvarez-Ponce, D. and Smirnova, E. (2020).** Emerging priorities for microbiome research. Front. Microbiol., **11**:491374.

**D'Argenio, V. and Salvatore, F. (2015).** The role of the gut microbiome in the healthy adult status. Clin. Chim. Acta, **451**:97-102.

**Doré, J. and Ortega Ugalde, S. (2023).** Human-microbes symbiosis in health and disease, on Earth and beyond planetary boundaries. Front. Astron. Space Sci., **10**:1180522.

**Dou, J. and Bennett, M. R. (2018).** Synthetic biology and the gut microbiome. Biotechnol. J., **13**(5):1700159.

**Eloe-Fadrosh, E. A. and Rasko, D. A. (2013).** The human microbiome: From symbiosis to pathogenesis. Annu. Rev. Med., **64**:145-163.

**El-Sayed, A.; Aleya, L. and Kamel, M. (2021).** Microbiota's role in health and diseases. Environ. Sci. Pollut. Res., **28**(28):36967-36983.

**Fessler, J.; Matson, V. and Gajewski, T. F. (2019).** Exploring the emerging role of the microbiome in cancer immunotherapy. J. Immunother. Cancer, **7**:1-5.

**Flowers, S. A. and Ellingrod, V. L. (2015).** The microbiome in mental health: Potential contribution of gut microbiota in disease and pharmacotherapy management. Pharmacotherapy, **35**(10):910-916.

**Gilbert, J. A.; Blaser, M. J.; Caporaso, J. G.; Jansson, J. K.; Lynch, S. V. and Knight, R. (2018).** Current understanding of the human microbiome. Nat. Med., **24**(4):392-400.

**Graumann, K. and Premstaller, A. (2006).** Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol. J., **1**(2):164-186.

**Graw, S.; Chappell, K.; Washam, C. L.; Gies, A.; Bird, J.; Robeson, M. S. and Byrum, S. D. (2021).** Multi-omics data integration considerations and study design for biological systems and disease. Mol. Omics, **17**(2):170-185.

**Grigoryan, Z.; Shen, M. J.; Twardus, S. W.; Beuttler, M. M.; Chen, L. A. and Bateman-House, A. (2020).** Fecal microbiota transplantation: Uses, questions, and ethics. Med. Microecol., **6**:100027.

**Gwak, M. G. and Chang, S. Y. (2021).** Gut-brain connection: Microbiome, gut barrier, and environmental sensors. Immune Netw., **21**(3).

**Hadrich, D. (2018).** Microbiome research is becoming the key to better understanding health and nutrition. Front. Genet., **9**:384416.

**Hills, R. D.; Pontefract, B. A.; Mishcon, H. R.; Black, C. A.; Sutton, S. C. and Theberge, C. R. (2019).** Gut microbiome: Profound implications for diet and disease. Nutrients, **11**(7):1613.

**Javdan, B.; Lopez, J. G.; Chankhamjon, P.; Lee, Y. C.; Hull, R.; Wu, Q.; Wang, X.; Chatterjee, S. and Donia, M. S. (2020).** Personalized mapping of drug metabolism by the human gut microbiome. Cell, **181**(7):1661-1679.

**Kanellopoulos, J. (2014).** Mammalian gut microbiota and immunity. Biomed. J., **37**(5):245.

**Kang, M.; Choe, D.; Kim, K.; Cho, B. K. and Cho, S. (2020).** Synthetic biology approaches in the development of engineered therapeutic microbes. Int. J. Mol. Sci., **21**(22):8744.

**Kelly, C. R.; Kunde, S. S. and Khoruts, A. (2014).**Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin. Gastroenterol. Hepatol., **12**(2):283-288.

**Kelly, L. (2019).** Harnessing the microbiome to improve drug therapy. Clin. Pharmacol. Ther., **106**(2):287-289.

**Khanna, S. and Tosh, P. K. (2014).** A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin. Proc., **89**(1):107-114.

**Khoury, M. J.; Gwinn, M.; Dotson, W. D. and Schully, S. D. (2012).** Knowledge integration at the center of genomic medicine. Genet. Med., **14**(7):643-647.

**Kogut, M. H.; Lee, A. and Santin, E. (2020).** Microbiome and pathogen interaction with the immune system. Poult. Sci., **99**(4):1906-1913.

**Lamousé-Smith, E.; Kelly, D. and De Cremoux, I. (2021).** Designing bugs as drugs: Exploiting the gut microbiome. Am. J. Physiol. Gastrointest. Liver Physiol., **320**(3):G295-G303.

**Lee, S. Y.; Lee, E.; Park, Y. M. and Hong, S. J. (2018).** Microbiome in the gut-skin axis in atopic dermatitis. Allergy Asthma Immunol. Res., **10**(4):354.

**Lee, Y. K. and Mazmanian, S. K. (2010).** Has the microbiota played a critical role in the evolution of the adaptive immune system? Science., **330**(6012):1768-1773.

**Li, L. (2011).** Symbiotic gut microbiota and the modulation of human metabolic phenotypes. Metagenomics Hum. Body, 297-306.

**Logotheti, M.; Agioutantis, P.; Katsaounou, P. and Loutrari, H. (2021).** Microbiome research and multi-omics integration for personalized medicine in asthma. J. Pers. Med., **11**(12):1299.

**Longman, R. S. and Littman, D. R. (2015).** The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity. Curr. Opin. Rheumatol., **27**(4):381-387.

**Louie, B.; Mork, P.; Martin-Sanchez, F.; Halevy, A. and Tarczy-Hornoch, P. (2007).** Data integration and genomic medicine. J. Biomed. Inform., **40**(1):5-16.

**Ma, N.; Tian, Y.; Wu, Y. and Ma, X. (2017).**Contributions of the interaction between dietary protein and gut microbiota to intestinal health. Curr. Protein Pept. Sci., **18**(8):795-808.

**Malard, F.; Doré, J.; Gaugler, B. and Mohty, M. (2021).**Introduction to host microbiome symbiosis in health and disease. Mucosal Immunol., **14**(3):547-554.

**Mimee, M.; Citorik, R. J. and Lu, T. K. (2016).** Microbiome therapeutics-advances and challenges. Adv. Drug Deliv. Rev., **105**:44-54.

**Mohajeri, M. H.; Brummer, R. J.; Rastall, R. A.; Weersma, R. K.; Harmsen, H. J.; Faas, M. and Eggersdorfer, M. (2018).** The role of the microbiome for human health: From basic science to clinical applications. Eur. J. Nutr., **57**:1-4.

**Monda, V.; Villano, I.; Messina, A.; Valenzano, A.; Esposito, T.; Moscatelli, F.; Viggiano, A.; Cibelli, G.; Chieffi, S.; Monda, M. and Messina, G. (2017).** Exercise modifies the gut microbiota with positive health effects. Oxid. Med. Cell. Longev., 2017.

**Paton, A. W.; Morona, R. and Paton, J. C. (2012).** Bioengineered microbes in disease therapy. Trends Mol. Med., **18**(7):417-425.

**Pedrolli, D. B.; Ribeiro, N. V.; Squizato, P. N.; de Jesus, V. N.; Cozetto, D. A.; Tuma, R. B.; Gracindo, A.; Cesar, M. B.; Freire, P. J.; da Costa, A. F. and Lins, M. R. (2019).** Engineering microbial living therapeutics: The synthetic biology toolbox. Trends Biotechnol., **37**(1):100-115.

**Petersen, C. and Round, J. L. (2014).** Defining dysbiosis and its influence on host immunity and disease. Cell. Microbiol., **16**(7):1024-1033.

**Pham, J. V.; Yilma, M. A.; Feliz, A.; Majid, T. M.; Maffetone, N.; Walker, J. R.; Kim, E.; Cho, H. J.; Reynolds, J. M.; Song, M. C. and Park, S. R. (2019).** A review of the microbial production of bioactive natural products and biologics. Front. Microbiol., **10**:449147.

**Pucker, B.; Schilbert, H. M. and Schumacher, S. F. (2019).**Integrating molecular biology and bioinformatics education. J. Integr. Bioinform., **16**(3):20190005.

**Putignani, L.; Del Chierico, F.; Petrucca, A.; Vernocchi, P. and Dallapiccola, B. (2014).** The human gut microbiota: A dynamic interplay with the host from birth to senescence settled during childhood. Pediatr. Res., **76**(1):2-10.

**Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D. and Peng, Y. (2012).** A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, **490**(7418):55-60.

**Ramakrishna, B. S. (2013).** Role of the gut microbiota in human nutrition and metabolism. J. Gastroenterol. Hepatol., **28**:9-17.

**Rhodes, R.; Gligorov, N. and Schwab, A. P. (2013).** The human microbiome: Ethical, legal and social concerns. Oxford University Press.

**Sanders, D. J.; Inniss, S.; Sebepos-Rogers, G.; Rahman, F. Z. and Smith, A. M. (2021).** The role of the microbiome in gastrointestinal inflammation. Biosci. Rep., **41**(6):BSR20203850.

**Schmidt, H. (1998).** Integrating the teaching of basic sciences, clinical sciences, and biopsychosocial issues. Acad. Med., **73**(9):S24-S31.

**Schupack, D. A.; Mars, R. A.; Voelker, D. H.; Abeykoon, J. P. and Kashyap, P. C. (2022).**The promise of the gut microbiome as part of individualized treatment strategies. Nat. Rev. Gastroenterol. Hepatol., **19**(1):7-25.

**Sharma, S.; Chaubey, K. K.; Singh, S. V. and Gupta, S. (2022).** Symbiotic microbiota: A class of potent immunomodulators. Science, Asia, **48**(6).

**Sirisinha, S. (2016).** The potential impact of gut microbiota on your health: Current status and future challenges. Asian Pac. J. Allergy Immunol., **34**(4):249-264.

**Suman, J.; Rakshit, A.; Ogireddy, S. D.; Singh, S.; Gupta, C. and Chandrakala, J. (2022).** Microbiome as a key player in sustainable agriculture and human health. Front. Soil Sci., **2**:821589.

**Tan, X. and Johnson, S. (2019).** Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'. Anaerobe, **60**:102092.

**Tang, W. W.; Kitai, T. and Hazen, S. L. (2017).** Gut microbiota in cardiovascular health and disease. Circ. Res., **120**(7):1183-1196.

**Thursby, E. and Juge, N. (2017).** Introduction to the human gut microbiota. Biochem. J., **474**(11):1823-1836.

**Tremaroli, V. and Bäckhed, F. (2012).** Functional interactions between the gut microbiota and host metabolism. Nature, **489**(7415):242-249.

**Turnbaugh, P. J.; Ley, R. E.; Mahowald, M. A.; Magrini, V.; Mardis, E. R. and Gordon, J. I. (2006).** An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, **444**(7122):1027-1031.

**Wang, Z.; Klipfell, E.; Bennett, B. J.; Koeth, R.; Levison, B. S.; DuGar, B.; Feldstein, A. E.; Britt, E. B.; Fu, X.; Chung, Y. M. and Wu, Y. (2011).**Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, **472**(7341):57-63.

**Weersma, R. K.; Zhernakova, A. and Fu, J. (2020).** Interaction between drugs and the gut microbiome. Gut, **69**(8):1510-1519.

**Wilkins, L. J.; Monga, M. and Miller, A. W. (2019).** Defining dysbiosis for a cluster of chronic diseases. Sci. Rep., **9**(1):12918.

**Wissel, E. F. and Smith, L. K. (2019).** Inter-individual variation shapes the human microbiome. Behav. Brain Sci., 42.

**Yadav, A. N.; Kumar, R.; Kumar, S.; Kumar, V.; Sugitha, T. C.; Singh, B.; Chauahan, V. S.; Dhaliwal, H. S. and Saxena, A. K. (2017).** Beneficial microbiomes: Biodiversity and potential biotechnological applications for sustainable agriculture and human health. J. Appl. Biol. Biotechnol., **5**(6):45-57.

**Zhang, F.; Luo, W.; Shi, Y.; Fan, Z. and Ji, G. (2012).** Should we standardize the 1,700-year-old fecal microbiota transplantation? Am. J. Gastroenterol., **107**(11):1755.

**Zhou, X.; Shen, X.; Johnson, J. S.; Spakowicz, D. J.; Agnello, M.; Zhou, W.; Avina, M.; Honkala, A.; Chleilat, F.; Chen, S. J. and Cha, K. (2024).** Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease. Cell Host Microbe., **32**(4):506-26.

**Citation** **Anas Islam, Badruddeen, Mohammad Irfan Khan, Juber Akhtar, Asad Ahmad, Mohammad Ahmad, Akash Srivastava and Shaiber Siddiqui (2025). The Microbiome's role in health and disease: Emerging therapeutic interventions and challenges. J. Phytonanotech. Pharmaceut. Sci., 5(2):7-15. http://dx.doi.org/10.54085/jpps.2025.5.2.2**